Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
14 mars 2022 16h05 HE
|
Sema4
37% increase in fourth quarter test volumes (excluding COVID-19 tests) compared to the same period last year Record quarterly test volume of nearly 83,000 24% growth in fourth quarter revenue...
Sema4 Named to Fast Company’s Annual List of the World’s Most Innovative Companies for 2022
08 mars 2022 08h00 HE
|
Sema4
STAMFORD, Conn., March 08, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, has been named to Fast Company’s prestigious annual...
Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022
22 févr. 2022 16h05 HE
|
Sema4
STAMFORD, Conn., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced it will release financial results for...
Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine
22 févr. 2022 08h00 HE
|
Sema4
STAMFORD, Conn. and BOSTON and TORONTO, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, and BioSymetrics, a...
Sema4 to Participate at Two Upcoming Investor Conferences in February
03 févr. 2022 16h05 HE
|
Sema4
STAMFORD, Conn., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that company management will...
Sema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement Capabilities
01 févr. 2022 07h30 HE
|
Sema4
STAMFORD, Conn., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced plans to strengthen its Market Access...
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
18 janv. 2022 07h00 HE
|
Sema4
Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify...
Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021
10 janv. 2022 07h15 HE
|
Sema4
STAMFORD, Conn., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced preliminary revenue (unaudited) for the...
Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January
03 janv. 2022 16h05 HE
|
Sema4
STAMFORD, Conn., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Sema4 (Nasdaq: SMFR), an AI-driven genomic and clinical data intelligence platform company, today announced that Eric Schadt, PhD, Founder and...
Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights
15 nov. 2021 16h01 HE
|
Sema4
36% increase in test volume (excluding COVID-19 tests) compared to the same period last year 17% growth in revenue (excluding COVID-19 tests) compared to the same period last year ...